United States
What CFOs learned by going through a virtual IPO: hiring, roadshow planning and the process of getting vetted by an outside accounting firm.
Biden plans to expand Medicare, a move that the Congressional Budget Office estimates would cut drug spending by $450 billion over 10 years.
With the election approaching, RSM is looking at the economic stakes and the key issues for the life sciences industry.
We suggest stress-testing your supply chain to determine what the actual or opportunity costs of disruption might be.
For companies that may have dealt with a lab closure because of the pandemic, Scientist.com allows research to continue.
Amid the COVID-19 pandemic, life sciences companies, thrust in the spotlight, are positioned for strong growth.
Applications to sell unused state net operating losses and state research and development credits available the week of May 1, 2020.
Here are some ways coronavirus could leave its mark on the global VAT, trade and tariff landscape for the life sciences industry.
The AICPA released the SOC for Supply Chain report to aid organizations with relevant controls to address business risk.
Proper evaluation can help life sciences companies prevent the undue state tax exposures when launching a new drug.
Emerging technology and life sciences companies can apply for a refundable tax credit for their qualifying investments.
Three states have prescriptions for opioid taxes on manufacturers and distributors. Here’s what you need to know.
Notwithstanding unfavorable changes to the Code, capital gain treatment is still available on the sale of patents in certain scenarios.
From contract research organizations to initial public offerings, life sciences finance leaders discuss issues in the bioscience businesses.
What’s the secret to successful supply chain outsourcing in your life sciences business? Learn how technology can make the difference.
Pharmaceutical, biotech and medical device company finance leaders discuss ASC 842 lease accounting adoption complexities and challenges.
What can life sciences businesses do to ensure data protection, especially with their third parties? Get key cybersecurity considerations.
Skepticism regarding artificial intelligence is understandable, but it’s often based on a misunderstanding of what AI really is.
How can life sciences companies looking to go public position themselves for success? It’s all about setting the stage early on.
Patient support programs can become a risk to life sciences product manufacturers if used to gain preferential treatment for their products.